![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Continued Treatment of Early Nonresponders or Partial Virologic Responders With Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta Through Week 96 Leads to Improvement in Virologic and Biochemical Responses
|
|
|
EASL 2023 June 23 Vienna
Pietro Lampertico1,2, Heiner Wedemeyer3, Maurizia Rossana Brunetto4, Pavel Bogomolov5, Tatyana Stepanova6, Sandra Ciesek7, Annemarie Berger7, Dmitry Manuilov8, Qi An8, Audrey H Lau8, Ben L Da8, John F Flaherty8,
Renee-Claude Mercier8, Stefan Zeuzem9, Markus Cornberg3, Maria Buti10, Soo Aleman11
![0627231](../images/062723/062623-16/0627231.gif)
![0627232](../images/062723/062623-16/0627232.gif)
![0627233](../images/062723/062623-16/0627233.gif)
![0627234](../images/062723/062623-16/0627234.gif)
![0627235](../images/062723/062623-16/0627235.gif)
![0627236](../images/062723/062623-16/0627236.gif)
![0627237](../images/062723/062623-16/0627237.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|